Cinctive Capital Management LP Boosts Stock Position in NewAmsterdam Pharma (NASDAQ:NAMS)

Cinctive Capital Management LP raised its position in shares of NewAmsterdam Pharma (NASDAQ:NAMS) by 77.7% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 66,571 shares of the company’s stock after buying an additional 29,115 shares during the period. Cinctive Capital Management LP’s holdings in NewAmsterdam Pharma were worth $1,105,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the company. Rosalind Advisors Inc. purchased a new stake in NewAmsterdam Pharma during the second quarter valued at approximately $194,000. Banque Cantonale Vaudoise purchased a new stake in shares of NewAmsterdam Pharma during the 2nd quarter valued at $38,000. Wolverine Asset Management LLC boosted its position in shares of NewAmsterdam Pharma by 117.7% in the 2nd quarter. Wolverine Asset Management LLC now owns 15,524 shares of the company’s stock worth $298,000 after purchasing an additional 8,394 shares in the last quarter. Sei Investments Co. grew its stake in NewAmsterdam Pharma by 49.1% during the 2nd quarter. Sei Investments Co. now owns 24,561 shares of the company’s stock worth $472,000 after buying an additional 8,087 shares during the last quarter. Finally, Affinity Asset Advisors LLC increased its position in NewAmsterdam Pharma by 47.9% during the 2nd quarter. Affinity Asset Advisors LLC now owns 423,155 shares of the company’s stock valued at $8,129,000 after buying an additional 136,955 shares in the last quarter. 89.89% of the stock is currently owned by institutional investors.

NewAmsterdam Pharma Trading Up 1.7 %

Shares of NASDAQ:NAMS opened at $19.98 on Wednesday. NewAmsterdam Pharma has a twelve month low of $8.90 and a twelve month high of $26.35. The company’s 50 day moving average is $19.63 and its 200 day moving average is $18.56.

Insider Activity

In other news, major shareholder Nap B.V. Forgrowth sold 8,530 shares of the company’s stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $25.02, for a total value of $213,420.60. Following the sale, the insider now owns 11,812,033 shares in the company, valued at $295,537,065.66. This represents a 0.07 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Louise Frederika Kooij sold 45,000 shares of NewAmsterdam Pharma stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $15.72, for a total value of $707,400.00. The disclosure for this sale can be found here. Insiders have sold 86,803 shares of company stock valued at $1,755,307 in the last ninety days. Insiders own 19.50% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on NAMS shares. Piper Sandler restated an “overweight” rating and set a $37.00 price target on shares of NewAmsterdam Pharma in a research note on Monday, September 23rd. Needham & Company LLC reissued a “buy” rating and set a $36.00 target price on shares of NewAmsterdam Pharma in a research report on Thursday, November 21st. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $31.00 price target on shares of NewAmsterdam Pharma in a report on Thursday, September 5th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $33.80.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.